http://www.reportbuyer.com/rss.htmlA concise collection of reports on CNS, data includes Drug Discoveries, Disorders, Prospects and Opportunities.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/global_multiple_sclerosis_market_2009_2024.htmlGlobal Multiple Sclerosis Market will expand steadily from 2009 to 2024 - new report explainsThe multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. The World Health Organization estimates that over 2. 8a324b38aee71788cba8657c375a66fdThu, 19 Mar 2009 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/neurodegenerative_market_forecast_2013_1.htmlComprehensive Forecasts for Neurodegenerative Conditions The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts: Sales among all drugs profiled in this report total $18. 5 billion and are expected to increase 62% to $29. 591616ed35215f559886a7a974b03062Mon, 02 Feb 2009 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/neurodegenerative_diseases.htmlNeurodegenerative diseases are drawing immense interest from the pharmaceutical industry and have inspired heavy competition in the race to introduce the next generation of improved drugs. Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are analyzed in this report, which: Reviews their symptoms and pathology, presumed causes, methods of diagnosis, epidemiology Examines existing drug therapies for each disorder Surveys the R&D picture for each disease Tabulates the approximately 150 compounds in clinical development Discusses particularly noteworthy drug candidates. Neurodegenerative diseases are caused by the loss or dysfunction of neurons in the brain or spinal cord. 921b6fe318105a972e343224772e96fcFri, 12 Dec 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/stakeholder_opinions_restless_legs_syndrome_novel_drugs_prosper_lifecycle_management_strategies_fail.html Restless legs syndrome (RLS) is a neurological condition, which affects 15. 5 million medically significant sufferers across the seven major markets (7MM). Through Requip (ropinirole) and Mirapex's (pramipexole) regulatory approvals in 200506, GlaxoSmithKline and Boehringer Ingelheim pioneered the onlabel RLS market, which reached $588m in 2007 across the 7MM. 569a35daae9c72c5809ab1dc739ce66aTue, 11 Nov 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/pipeline_commercial_insight_anxiety_disorders_viable_indication_antipsychotics_companies.html Despite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergicbased treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and maintain market share is growing as the patent expiries of three major brands draws near. a59475f6f71787185cd7a3e27a35ab90Tue, 11 Nov 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_market_outlook_2013_competitive_landscape_pipeline_analysis_growth_opportunities.htmlThe CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. 2c80de22574591fedb440ebc6e0ef224Tue, 09 Sep 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_drug_discoveries_depression.htmlEspicom's best-selling CNS Drug Discoveries: what the future holds provides a comprehensive examination of 5 major CNS therapy areas: multiple sclerosis, Alzheimer's disease, Parkinson's disease, schizophrenia and depression. The information below and the ordering information on this page relate to the depression chapter.    DepressionAntidepressants accounted for around 21% of the total CNS drug sales in 2007, with sales of US$19. afce17e91d5d188aa5d18069689ae080Fri, 15 Aug 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_drug_discoveries_future_holds_2008_full_report.htmlUnique market share and sales forecasts by product to 2014 A comprehensive examination of 5 major CNS therapy areas Detailed competitor analysis of current and upcoming products Five key CNS sectors Alzheimer's disease Multiple sclerosis Depression Parkinson's disease Schizophrenia With this new 4000+ page analysis you can. . . eeddc14c3e3271f117956e8c534e85ffThu, 14 Aug 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_drug_discoveries_multiple_sclerosis.htmlEspicom's best-selling CNS Drug Discoveries: what the future holds provides a comprehensive examination of 5 major CNS therapy areas: multiple sclerosis, Alzheimer's disease, Parkinson's disease, schizophrenia and depression. The information below and the ordering information on this page relate to the multiple sclerosis chapter. To find out more about the full report, click here. 3f4b50d4d70f49d6cbd9e0b29078c92bFri, 01 Aug 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_therapeutics.htmlThis report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product Groups analyzed are Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. cc233a90e76a39f90d0c0ac678b8b622Mon, 05 May 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_generic_drugs_prospects_opportunities_2012.htmlThis important new strategic report evaluates the CNS generic drug market sector and answers key questions such as: What is the patent and data exclusivity status of Shire's ADHD drug Adderall? What impact on sales of GSK's Seroxat/Paxil will generic competition have from 2007? What opportunities exist for Wyeth's valuable SSNRI Effexor? What strategies are sanofi-aventis employing in defence of its best selling insomnia treatment Ambien? Only Exelon is currently available generically for the treatment of Alzheimer's - what is the potential of the other leading treatments Aricept (Eisai), Razadyne (Janssen) and Namenda (Forest Labs)? What's in the pipeline? New branded products that will compete with generics in the future. Why will sales of Eli Lilly's Zyprexa remain constant over the next 5 years despite rising generic availability? What are Dr Reddy's CNS drug interests? In 2007, Caraco Pharmaceuticals received 3 ANDA approvals for CNS drugs. What were they and in what dosages? One of the fastest growing drug sectors in terms of product and market value, CNS presents the generics industry with much needed on-going product opportunities Antidepressant sales in 2005 were approximately US$16. 6cd24d7ac53b18c0590c92938afbd0f6Fri, 25 Apr 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/commercial_insight_cns_market_overview.html The market for CNS drugs across the 7MM was worth a substantial $95. 5 billion, accounting for a 21. 4% share of the total pharmaceutical market value in 2007. d8956c30b717f1041bd96d9990d5deb3Thu, 17 Apr 2008 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/alzheimers_disease_market_analysis_forecasts_2007_2012_2017_2022.htmlPlease Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order,the client will receive an email with information on accessing their purchase. 20919bb81952cb63132081f47e1ae0a9Mon, 15 Oct 2007 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_market_outlook_2012.htmlCNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer's and Parkinson's disease. 'The CNS Market Outlook to 2012' is a new report published by Business Insights that provides a detailed epidemiological analysis of major indications within the CNS disorders market, and examines the factors impacting their prevalence. 1816d9ddc2abd4e3a111879aef6ed9d9Mon, 01 Oct 2007 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/pipeline_commercial_insight_parkinsons_disease.html The PD market is set to continue to grow over the next 7 years, reaching over $2. 37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro. 50523e9b0b94feddfaa6eae7a606d6e3Fri, 28 Sep 2007 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/commercial_insight_migraine.html With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8. 1% from 2005 to $3. 7 billion in 2006. aee0465288419f114c8743fee661923eWed, 26 Sep 2007 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/commercial_insight_epilepsy.html The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2. 3% from 2005 to $3. 79ec2ccdbb0a9a4a17b078af1751f56fWed, 26 Sep 2007 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/pipeline_insight_neuropathic_pain.html The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management. The most promising and closest pipeline drug to market is UCB's Vimpat (lacosamide). 3203ea1a419708dca9d2cc23f2f0f578Wed, 26 Sep 2007 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/cns_market_trends_2007_2010.htmlThe global market for drugs treating Central Nervous System (CNS) disorders has grown rapidly in recent years to reach US$55. 5 billion in 2005, a year-on-year increase of 6. 6%. 10135ed2eed2e109a0567a5e9ebd04a6Sat, 23 Jun 2007 12:00:00 GBDiseases/CNShttp://www.reportbuyer.com/pharma_healthcare/diseases/cns/neurodegenerative_disease_drug_market_analysis_forecasts_2007.htmlPlease Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order,the client will receive an email with information on accessing their purchase. 6b9712312a003a72e1a794cc9df7b098Fri, 15 Jun 2007 12:00:00 GBDiseases/CNS